AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9236433
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral carvedilol treatment
Trial: 31693806
Drug: Intravenous amoxicillin‐clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amoxicillin‐clavulanate (1 g and 200 mg, respectively) administered three times a day for 2 days, starting less than 6 hours after cardiac arrest.
Trial: 31693806
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered three times a day for 2 days, starting less than 6 hours after cardiac arrest.
Trial: 28577545
Drug: Intervention (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (two dietary consultations and access to twice‐weekly exercise groups)
Trial: 25082656
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg/day for three months
Trial: 21807696
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (400 mg daily from 18 to 22 weeks' gestation through parturition)
Trial: 17014635
Drug: Face washing
RxNorm normalized name: Phisoderm Clear Confidence Daily Gel Face Wash
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face washing twice a day with a standard mild cleanser
Trial: 17014635
Drug: Face washing
RxNorm normalized name: Phisoderm Clear Confidence Daily Gel Face Wash
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face washing twice a day (control group)
Trial: 10664923
Drug: IS‐5‐MN 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IS‐5‐MN 20 mg immediate release
Trial: 10664923
Drug: IS‐5‐MN 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IS‐5‐MN 50 mg sustained release
Trial: 9297869
Drug: i.v. omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. omeprazole, 40 mg bolus followed by 80 mg/day by continuous infusion for 3 days
Trial: 9297869
Drug: i.v. ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ranitidine 50 mg i.v. bolus followed by 400 mg/day i.v., continuous infusion for 3 days
Trial: 8345983
Drug: IVGG (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVGG (400 mg/kg/day for 4 consecutive days)
Trial: 30152049
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) of DEC and albendazole
Trial: 26801098
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (150 min weekly of combined aerobic and resistance training)
Trial: 22304620
Drug: Mentholated cream
RxNorm normalized name: camphor / menthol Topical Ointment [Mentholatum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentholated cream plus oxygenated glycerol triesters (MC + OGTs)
Trial: 22304620
Drug: Mentholated cream
RxNorm normalized name: camphor / menthol Topical Ointment [Mentholatum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentholated cream (MC)
Trial: 18514323
Drug: Schizophrenia patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schizophrenia patients with shorter duration of antipsychotic drug exposure
Trial: 8740043
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg phenelzine every other day, then 15 mg daily for 6 weeks
Trial: 1846872
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen (CEE) + 5 mg medroxyprogesterone acetate (days 15-25)
Trial: 1846872
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg CEE + placebo (days 15-25)
Trial: 1846872
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg CEE (days 1-25)
Trial: 1846872
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg CEE (days 1-25)
Trial: 6760968
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg oral dose)
Trial: 31232940
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg twice daily 1 day before and 3 days after the operation)
Trial: 31232940
Drug: Control (hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (hydration from 12 hours before to 12 hours after contrast administration)
Trial: 25916131
Drug: Intravenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous laser therapy (10-day course) using 'matrix-vlok' apparatus, wavelength 0.405 microns, radiation power 1-1.5 mW, continuous mode
Trial: 11471442
Drug: Normovolemic hemodilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normovolemic hemodilution (NVH) with blood withdrawal of 6-8 ml.kg-1 and intravenous colloid substitution
Trial: 7865434
Drug: Paclitaxel 250
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 250 mg/m2 i.v. over 24 hours every 3 weeks
Trial: 7865434
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 to 250 mg/m2 i.v. over 24 hours every 3 weeks
Trial: 7865434
Drug: Cisplatin/etoposide chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/etoposide chemotherapy (standard)
Trial: 7865434
Drug: Paclitaxel 135
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 135 mg/m2 i.v. over 24 hours plus cisplatin 75 mg/m2 i.v.
Trial: 7865434
Drug: Paclitaxel 250
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 250 mg/m2 i.v. over 24 hours plus cisplatin 75 mg/m2 i.v. plus recombinant human granulocyte colony-stimulating factor
Trial: 2494240
Drug: Transdermal nitroglycerin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin, 10 or 20 cm2 (5 or 10 mg/24 h) (Group A)
Trial: 2494240
Drug: Transdermal nitroglycerin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin, 30 or 40 cm2 (15 or 20 mg/24 h) (Group B)
Trial: 31537025
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg/day)
Trial: 31537025
Drug: Deflazacort (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort (30 mg/day)
Trial: 31537025
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Tamsulosin and Deflazacort)
Trial: 31537025
Drug: Paracetamol on
RxNorm normalized name: Paracetamol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol on demand (Control group)
Trial: 25062611
Drug: Bacillus subtilis
RxNorm normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus subtilis R0179 at 0.1×10^9 cfu/capsule/day
Trial: 25062611
Drug: Bacillus subtilis
RxNorm normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus subtilis R0179 at 1.0×10^9 cfu/capsule/day
Trial: 25062611
Drug: Bacillus subtilis
RxNorm normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus subtilis R0179 at 10×10^9 cfu/capsule/day
Trial: 21282540
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 100 mg/d
Trial: 21282540
Drug: Warfarin (WAR)
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (WAR) 1.25 mg/d
Trial: 21282540
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - Enoxaparin 40 mg/d
Trial: 18164303
Drug: Goserelin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.6 mg subcutaneous depot every 4 weeks for 3 doses)
Trial: 18164303
Drug: Leuprolide (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (3.75 mg subcutaneous depot every 4 weeks for 3 doses)
Trial: 16474028
Drug: Rifapentine 900
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 900 mg/isoniazid 900 mg once weekly for 12 weeks
Trial: 16474028
Drug: Rifampin 450-600
RxNorm normalized name: rifampin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 450-600 mg/pyrazinamide 750-1,500 mg daily for 8 weeks
Trial: 8864797
Drug: Fenofibrate 250
RxNorm normalized name: fenofibrate 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 250 mg retard capsules
Trial: 8864797
Drug: Lipanthyl 250
RxNorm normalized name: Lipanthyl
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lipanthyl 250 mg retard capsules
Trial: 1617931
Drug: amoxicillin‐clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin‐clavulanic acid (500 mg/125 mg t.i.d.)
Trial: 6366550
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with fluorouracil and semustine
Trial: 6366550
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with methanol extraction residue of BCG
Trial: 6366550
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with fluorouracil, semustine, and immunotherapy
Trial: 6366550
Drug: Close follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Close follow-up without adjuvant treatment
Trial: 27393505
Drug: para-toluenesulfonamide (PTS)
RxNorm normalized name: o-toluenesulfonamide
DrugBank: p-Toluenesulfonamide (DB17299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: para-toluenesulfonamide (PTS) intratumoral injection
Trial: 20942940
Drug: Erythropoietin (Epo)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (Epo) 40,000 IU weekly infusions for 8 weeks
Trial: 20942940
Drug: Saline (NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (NaCl 0.9%) weekly infusions for 8 weeks
Trial: 16803917
Drug: Subarachnoid block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid block (SAB) with bupivacaine, clonidine, and morphine
Trial: 10875189
Drug: Progressive relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive relaxation (PR) treatment for insomnia
Trial: 9663828
Drug: Budesonide 3
RxNorm normalized name: budesonide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 3 mg t.d.s. for 6 months
Trial: 3947124
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% minoxidil solution
Trial: 25204509
Drug: Landiolol 2
RxNorm normalized name: Landiolol 280 MG Intravenous Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 2 μg/kg/min (Group L2)
Trial: 25204509
Drug: Landiolol 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 5 μg/kg/min (Group L5)
Trial: 24067398
Drug: Dexpramipexole 150
RxNorm normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexpramipexole 150 mg twice daily
Trial: 10917405
Drug: Codeine 180
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine 180 mg
Trial: 10917405
Drug: Quinidine single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine single-dose (50 mg)
Trial: 10917405
Drug: Quinidine short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine short-term (50 mg four times a day for 4 days)
Trial: 8768938
Drug: Risperidone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2 < max <= 5 mg)
Trial: 8768938
Drug: Risperidone (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (higher than 15 mg)
Trial: 8768938
Drug: Risperidone (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (higher than 10 mg)
Trial: 1348750
Drug: Immediate intravenous
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate intravenous beta‐adrenergic blocking agent therapy
Trial: 1348750
Drug: Deferred beta‐blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred beta‐blocker therapy
Trial: 2940091
Drug: beta-adrenoceptor blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-adrenoceptor blocker metoprolol (n = 88)
Trial: 2940091
Drug: thiazide diuretic
RxNorm normalized name: Thiazide diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thiazide diuretic hydrochlorothiazide (n = 80)
Trial: 27554670
Drug: 1250 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg/day omega-3 fatty acid + alpha-tocopherol placebo
Trial: 27554670
Drug: 1250 mg
RxNorm normalized name: bran 1250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg omega-3 fatty acids/day + 400 IU/day alpha-tocopherol
Trial: 9509213
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (Group A)
Trial: 24647296
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose (Group B)
Trial: 24647296
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EMLA cream and oral sucrose (Group C)
Trial: 22590998
Drug: Vaginal preparation
RxNorm normalized name: Trichomonas vaginalis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal preparation with povidone-iodine solution
Trial: 22590998
Drug: No vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vaginal preparation (control)
Trial: 20217116
Drug: Sodium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium intake reduced to approximately 1,500 mg/day
Trial: 20217116
Drug: Habitual sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habitual sodium intake of approximately 3,000 mg/day
Trial: 18555934
Drug: Doripenem 500
RxNorm normalized name: doripenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doripenem 500 mg IV q8h
Trial: 18555934
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g IV q8h
Trial: 7821474
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac 0.1% pretreatment
Trial: 7821474
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no topical diclofenac)
Trial: 31462310
Drug: Si-ni-tang (SNT)
RxNorm normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Si-ni-tang (SNT) 150 mL per day for 3 days
Trial: 31462310
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 150 mL per day for 3 days
Trial: 21901285
Drug: Sibutramine (pharmacotherapy)
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine (pharmacotherapy) for 1 year
Trial: 21901285
Drug: BIB/pharmacotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIB/pharmacotherapy after BIB removal
Trial: 21901285
Drug: BIB/lifestyle or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIB/lifestyle or BIB/pharmacotherapy
Trial: 21901285
Drug: Pharmacotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy group
Trial: 19623780
Drug: Topical products
RxNorm normalized name: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical products designed to improve skin barrier function, hydration, and skin turnover
Trial: 19623780
Drug: Topical products
RxNorm normalized name: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical products
Trial: 12142121
Drug: Salbutamol (Salb)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol (Salb) 400 microg administered via inhalation after intravenous N‐omega‐nitro‐monomethyl‐L‐arginine (L‐NMMA) 3 mg/kg over 5 min
Trial: 12142121
Drug: Salbutamol (Salb)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol (Salb) 400 microg administered via inhalation after control solution (normal saline)
Trial: 12142121
Drug: Salbutamol (Salb)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol (Salb) after L‐NMMA
Trial: 10547221
Drug: Intracoronary ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary ketanserin (1.5 mg in 10 ml normal saline administered over 3 min)
Trial: 8703545
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy with doses ranging from 45 to 50 Gy in the compartmental volume after complete resection, and from 55 to 60 Gy in the tumor bed after marginal or incomplete resection.
Trial: 526382
Drug: etomidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etomidate 0.3 mg kg‐1 preceded by fentanyl 1.25 or 2.5 microgram kg‐1 i.v.
Trial: 526382
Drug: etomidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etomidate 0.3 mg kg‐1 preceded by diazepam 0.0625 or 0.125 mg kg‐1 i.v.
Trial: 526382
Drug: etomidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etomidate 0.3 mg kg‐1 preceded by fentanyl 2.5 microgram kg‐1 i.v.
Trial: 27853925
Drug: Fluoride gel
RxNorm normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride gel applications with intensive dental prevention in kindergarten
Trial: 27853925
Drug: Fluoride gel
RxNorm normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride gel applications without intensive dental prevention in kindergarten
Trial: 27853925
Drug: Maximum group
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum group prevention (intensive prevention in kindergarten and gel program at school)
Trial: 25868203
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil (FA) 1 mg x kg(‐1) administered at the end of surgery, n = 20
Trial: 25868203
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no FA administration), n = 20
Trial: 23601744
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg once daily (QD)
Trial: 23601744
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg twice daily (BID)
Trial: 23601744
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg BID
Trial: 23601744
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg QD
Trial: 23601744
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg QD
Trial: 23601744
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg BID
Trial: 19873917
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Cinnarizine, Cyproheptadine and Vitamin E
Trial: 16625520
Drug: Experimental HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental HIV vaccine
Trial: 9741369
Drug: Theophylline (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (600 or 800 mg daily)
Trial: 9741369
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of theophylline and ipratropium bromide
Trial: 3195055
Drug: NIVGRIP trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIVGRIP trivalent inactivated influenza vaccine
Trial: 29390493
Drug: Ping Chuan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ping Chuan Ke Li (PCKL) plus oral montelukast
Trial: 29390493
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus oral montelukast
Trial: 26188003
Drug: Sildenafil, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil, 60 mg three times a day for 12 weeks
Trial: 17096718
Drug: HL-450 (0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL-450 (0.45 g/100 mL)